Asia Pacific Shifts Focus to Local Diagnostics

APAC’s diagnostics sector is reshaping, with a market value of more than $38 billion spread across six key economies that are each carving out distinct capabilities.

China’s scale and genomics drive

China leads the region with an in‑vitro diagnostics (IVD) market valued at $18.65 billion in 2025, according to market forecasts. The sector is projected to reach $24.92 billion by 2031, growing at just under 5 percent annually. Over 1,400 IVD manufacturers operate in the country, including firms such as Mindray, Snibe, Autobio Diagnostics and BGI Genomics.

Analysts point to the nation’s large patient pool, strong government backing for precision‑medicine initiatives, and rapid development of sequencing, bioinformatics and AI‑based interpretation as the main forces behind this growth.

Oncology testing dominates the Chinese market, with liquid‑biopsy and circulating‑tumor‑DNA technologies emerging faster than many competitors can track. The government’s focus on Alzheimer’s disease also spurs investment in blood‑based biomarkers, reflecting the country’s ageing demographics.

Japan’s mature ecosystem

Japan’s diagnostics setting combines IVD and imaging strengths. Mordor Intelligence projects the IVD segment to climb from $7.29 billion in 2025 to $9.46 billion by 2031, while diagnostic imaging equipment is expected to rise from $2.85 billion to $4.02 billion in the same period. Roughly 130 IVD firms, including Sysmex and Fujirebio, support a broad range of hematology, immunodiagnostics and molecular tests.

The country also hosts more than 230 medical‑technology companies, such as Canon Medical Systems and Olympus, that dominate MRI, CT and ultrasound markets. These firms are increasingly integrating AI‑assisted analysis and digital pathology into their product lines.

South Korea’s AI imaging niche

South Korea’s AI‑enabled imaging analytics market is valued at $1.2 billion, with about 27 firms focused on AI diagnostics. Companies like Lunit and Vuno provide AI tools for chest X‑ray, mammography and brain MRI interpretation, serving thousands of providers across more than 65 countries.

The country’s digital‑hospital environment and extensive clinical datasets support rapid validation of AI models. A government‑backed genome project aims to sequence one million Koreans, laying groundwork for population‑scale genomics.

India’s point‑of‑care push

India’s IVD market stands at $5.6 billion, anchored by roughly 171 domestic manufacturers. The sector concentrates on rapid test kits, lateral‑flow assays and portable PCR platforms that address the nation’s large, dispersed population.

Singapore and Australia: precision hubs

Singapore’s IVD market, though modest at $0.92 billion in 2023, punches above its weight as a precision‑medicine hub. The National Precision Medicine programme and the SG100K genome database aim to generate Asian‑relevant genomic insights for oncology and rare‑disease diagnostics.

Australia’s IVD market, estimated at $2.06 billion in 2026, is heavily import‑dependent but excels in clinical validation and bioinformatics. The country’s stringent regulatory environment and secure data infrastructure make it a trusted stepping‑stone for firms seeking broader APAC acceptance.

For clinicians and patients, these divergent strengths mean that a test developed in one corner of the region may soon be available locally, reducing turnaround times and logistical hurdles.

Future growth will be driven by AI integration across laboratory workflows, greater adoption of total‑lab automation, and a shift toward in‑country testing. A recent study demonstrated an AI auto‑verification system achieving an 89.6 percent pass rate while cutting invalid reports by roughly 80 percent, suggesting that automated review is moving from pilot projects to routine practice.

Data sovereignty concerns are also rising, with governments emphasizing the need for genomic data to stay within national borders while still enabling collaborative research.

Overall, the APAC diagnostics field is moving from a fragmented, import‑reliant model to a more interconnected ecosystem where each country contributes its unique capabilities, from China’s scale to Singapore’s governance, and from South Korea’s AI expertise to India’s frugal innovation.